Lexicon Pharmaceuticals, Inc.

Novo Nordisk has once again demonstrated its drive to stay on top in obesity, unveiling its second licensing deal in a matter of days. It will pay $75m upfront for rights to Lexicon’s LX9851, a first-

Lexicon Pharmaceuticals presented its Phase IIb data for pilavapadin (LX9211) on 3 March as a win that clarified the dosing regimen to take into Phase III in diabetic peripheral neuropathic pain (DPNP

Lexicon Pharmaceuticals has an important data readout coming in the first quarter for a Phase IIb study testing pilavapadin, or LX9211, for diabetic peripheral neuropathic pain (DPNP). If that trial r

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the